Vancouver, British Columbia — November 11, 2025 — Leads & Copy —
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) has extended its non-brokered private placement financing, initially announced on October 7, 2025, to allow more investors to participate. The offering is expected to close by November 20, 2025, or another date determined by the company, pending regulatory approvals, including acceptance from the Canadian Securities Exchange.
The offering includes a minimum of 10,588,235 units at $0.17 per unit, aiming to raise $1,800,000, and up to a maximum of 11,764,705 units for gross proceeds of up to $2,000,000. Each unit comprises one common share and one common share purchase warrant. Each warrant allows the holder to acquire an additional share at an exercise price of $0.40 within 24 months from the issuance date.
BioVaxys intends to use the proceeds to organically grow its pipeline by:
- Pursuing licensing opportunities and research collaborations with DPX to address specific needs, positioning the company as a partner for targeted immunotherapies.
- Identifying GLP supply or production of preclinical supply of DPX for research, preclinical supply of DPX+peanut antigen for the peanut allergy vaccine program, and proof of concept studies for DPX formulations in mRNA and neoantigens.
- Initiating a DPX food allergy program at McMaster University for a preclinical proof of concept study with a DPX peanut antigen prophylaxis vaccine candidate.
- Filing new patents and maintaining annuity payments for existing patents.
- Completing immunological data analysis from MVP-S phase 1 studies for out-licensing in other tumor types.
Finder’s fees may be paid to eligible finders who introduce subscribers to the company.
The units will be offered for sale to purchasers under the Listed Issuer Financing Exemption in Canadian provinces (excluding Quebec) and other qualifying jurisdictions. Securities issued under this exemption will not be subject to a hold period under Canadian securities laws.
An amended and restated offering document dated October 28, 2025, is available on SEDAR+ and the company’s website. Prospective investors should read this document before making investment decisions.
The securities have not been and will not be registered under the United States Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption. This news release is not an offer to sell or a solicitation to buy securities in the United States or any jurisdiction where such an offer would be unlawful.
BioVaxys Technology Corp. is a biopharmaceutical company focused on improving patient lives through immunotherapies based on the DPX™ immune-educating technology platform and HapTenix© tumor cell construct platform for treating cancers, infectious diseases, food allergies, and other immunological diseases. The company’s clinical-stage pipeline includes maveropepimut-S (MVP-S) for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant Ovarian Cancer. BioVaxys is also developing DPX™+SurMAGE, DPX™-RSV, DPX+rPA, and BVX-0918.
BioVaxys common shares are listed on the CSE under the symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace).
James Passin, CEO, can be contacted at james@biovaxys.com or +1 740 358 0555.
Source: BioVaxys Technology Corp.
